Dear Editor A FREQUENTLY used cautionary adage among competent analysts is that “Statistics don’t lie, liars use statistics.” Quite often, this adage also ...

Dianthus Therapeutics announces positive Phase II results for Claseprubart in myasthenia gravis, highlighting best-in-class potential.

By Marilyn Odendahl The Indiana Citizen September 4, 2025 At a public meeting held in Indianapolis on Wednesday to discuss ...

Gleneagles winning captain outlines the humble origins of the statistical work which will play a big role at Bethpage ...

In response to the needs of smart campus construction, Xi'an Medical College Library has officially launched a big data display platform, marking a solid step towards the digital and intelligent ...

Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered ...

U.S. INDICATIONS AND USAGE POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) ...

Marvell’s presentation provides a strong indication that the company is successfully executing its AI-focused strategy. The dramatic growth in data center revenue suggests that Marvell is capitalizing ...

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society ...

Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, ...

With a 35-year legacy in data services, Innodata has successfully pivoted to become a key player in the AI data engineering space. Quarterly Performance Highlights Innodata reported impressive ...

FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the ...